Michael Kormann

University of Tübingen Germany

Michael S.D. Kormann is currently an Assistant Professor for Translational Genomics and Gene Therapy at the University of Tübingen, Germany, and works at the University Children\'s Hospital - Section I - Pediatric Infectiology & Immunology. He obtained his PhD from Ludwig-Maximilians-University, Munich, Germany. Dr. Kormann serves as an Editor, Reviewer and Editorial Board member for many scientific journals and books. He is a member of several scientific societies, including German CF Association, and American Society of Gene and Cell Therapy. Dr. Kormann has a total of 22 publications with more than 800 citations. He has three patents and has won several awards and prizes for his work.

1books edited

1chapters authored

Latest work with IntechOpen by Michael Kormann

Site-specific endonucleases create double-strand breaks within the genome and can be targeted to literally any genetic mutation. Together with a repair template, a correction of the defective locus becomes possible. This book offers insight into the modern tools of genome editing, their hurdles and their huge potential. A new era of in vivo genetic engineering has begun.

Go to the book

Modern Tools for Genetic Engineering

Edited by Michael Kormann

Chapters authored

In vivo Gene Correction of Cystic Fibrosis

By Michael Sebastian Daniel Kormann

The cystic fibrosis transmembrane conductance regulator (CFTR) gene was cloned over two decades ago and a vast number of pre-clinical and clinical studies have been performed since that time. Despite this progress, a true "cure" for the disease has not been achieved, partly because the lung is a major barrier for intruders, making it exceedingly difficult for new pharmaceutical formulations to penetrate target cells. Safety-engineered viral vectors, such as adeno-associated viral vectors (AAVs) or integrase-defective lentiviruses, have been used with moderate success in temporarily supplementing the expression of critical proteins. However, stability and safety concerns often dampen the effects of these approaches. With emerging technologies, such as modified messenger (mRNA) and new genome editing strategies, scientists are now exploring the possibility of not only supplementing defective proteins, but instead, correcting the genetic defects at their source. This chapter will highlight the theoretical possibilities and primary data in pre-clinical models supporting the efforts toward in vivo gene correction of cystic fibrosis (CF).

Part of the book: Cystic Fibrosis in the Light of New Research

Michael Kormann

Latest work with IntechOpen by Michael Kormann

Modern Tools for Genetic Engineering

Chapters authored

Related collaborators

Noel G. McElvaney

Emer Reeves

Rosa Patricia Arias Llorente

Carlos Bousoño

David González-Jiménez

Juan José Diaz-Martín

Michelle White

Fatma Gargoum

Niall Browne

Killian Hurley